Optimi Health Shares Climb Following Ibogaine Supply Agreement

Optimi Health has secured a significant deal to provide naturally sourced ibogaine, a move that significantly impacted its stock performance. On Wednesday, the company's shares experienced a substantial rise, closing up nearly 23% at 19 cents U.S. The Vancouver-based enterprise, a licensed producer of psychedelics for therapeutic applications, revealed its partnership with ATAI Life Sciences. This collaboration positions Optimi Health to be a primary supplier of ibogaine for ATDAI’s clinical trials. ATDAI Bio Inc., a subsidiary of ATDAI Life Sciences and a leader in biopharmaceutical research, is concentrating on the development of addiction treatments. The agreement specifies that Optimi Health will furnish pharmaceutical-grade ibogaine to support ATDAI Bio's research initiatives. Investing.com reports that this supply is crucial for ATDAI Bio's planned Phase 1 clinical trial, which will evaluate the safety and pharmacology of a specific ibogaine formulation, IBX-101, for treating opioid use disorder. JJ Wilson, Chairman of Optimi Health, expressed the company’s pride in collaborating with ATDAI Life Sciences. He emphasized Optimi Health’s commitment to providing high-quality psychedelic compounds for clinical investigation, asserting that this partnership underscores their dedication to advancing global health solutions. This agreement follows Optimi Health’s receipt of an amendment to its dealer's license from Health Canada in June. The amendment permits the company to possess and conduct research with ibogaine, as well as to import and export it. This regulatory approval was a pivotal step, enabling Optimi to engage in such supply deals. ATDAI Life Sciences, headquartered in Berlin, is a biopharmaceutical firm focused on developing innovative mental health therapies. Their portfolio includes a range of psychedelic and non-psychedelic compounds aimed at addressing various neurological and psychiatric conditions. The strategic alliance with Optimi Health is expected to bolster ATDAI Bio’s ongoing efforts in psychedelic-assisted psychotherapy research.